PARP1 and gastric cancer: As an RNA m6A methyltransferase that catalyzes m6A, METTL3 was reported by Li et al. to be upregulated and promote oxaliplatin (the first-line treatment for advanced gastric cancer) resistance of CD133 + stem cells by enhancing PARP1 mRNA stability in gastric cancer [7].